Ignite Creation Date:
2024-05-05 @ 11:51 AM
Last Modification Date:
2024-10-26 @ 9:15 AM
Study NCT ID:
NCT00155714
Status:
WITHDRAWN
Last Update Posted:
2010-03-16
First Post:
2005-09-09
Brief Title:
Efficacy of Type-5 Phosphodiesterase Inhibitors in Primary and Secondary Pulmonary Hypertension
Sponsor:
National Taiwan University Hospital
Organization:
National Taiwan University Hospital
Study Overview
Official Title:
Clinical Efficacy of Type-5 Phosphodiesterase Inhibitors Sildenafil and Vadenafil in Primary and Secondary Pulmonary Hypertension
Status:
WITHDRAWN
Status Verified Date:
2010-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
We cant obtained the test drug Vadenafil from Bayer They decided not to carry out this trail in Taiwan Therefore this trail has never been started
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The aim of this trial is to evaluate the efficacy of type-5 phosphodiesterase inhibitors sildenafil in primary and secondary pulmonary hypertension
Detailed Description:
Patients with primary and secondary pulmonary hypertension will be recruited and admitted to the ICUs of the National Taiwan University Hospital Each patient will undergo Swan-Ganz catheterization and hemodynamic monitoring during administration of sildenafil Efficacy of inhaled NO and Iloprost will also be compared
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None